| Summary: | 碩士 === 國立中山大學 === 高階經營碩士班 === 93 === The government has included biological technology industries among the priorities of development program for “challenge 2008--national development plan” and “Two Trillions Double Stars Industries Development Plan”. As the labor cost rising and many industries moving to Mainland China, several traditional industries in Taiwan have successfully transformed into biological technology industries for surviving, while some pharmaceutical industries seems not to do well as above. So the author would like to dip out intensively why non-pharmaceutical industries could convert the investment into biological technology sectors successfully than the pharmaceutical counterparts. It would collect some relevant data and get interviews from respective company and literature review, and then apply SWOT (Strength, Weakness, Opportunity and Threats) analysis to understand what kinds of impediments those companies have encountered, how they resolved the problems and what results they yielded. May this study provide feasible advises about the optimal routes and approaches for Taiwan industries to transform into biological technology sectors by analyzing and comparing different cases of converted investment.
The results that have been found are as follows: the converted investments which non-pharmaceutical industries embarked upon could divided into two approaches--- one for those companies that had adequately understand their own merits and felt they should convert the investment into biological technology sectors; another one is that the transformed company only hoped to facilitate the opportunity which government prioritized to market their products well. In near future, we would see the biological technology industries come to merger, vertical integration and strategic alliance due to research & development, marketing access and acquirements of capitals. According to this survey, most pharmaceutical companies wouldn’t like to transform into biological technology industries because of some state policies, such as cGMP system, health insurance bureau lowering the payment for pharmaceutical companies, domestic markets having been liberated and new labor retirement pension fund systems. Besides, the pharmaceutical industries have been stepping up the speed of merger and shakeout, certainly would they not to transform into biological technology industries.
Therefore, if the domestic industries hope to convert their investments, they should layout short-term and long-term strategies, which the former ought to take priority of creating the profits so as to facilitate the development of the latter which would focus on building up marketing accesses, cultivating R&D talents and their competences, as well as expanding strategic alliance actively with international enterprises for biological technology. To conclude, this study would provide Taiwan industries who tried to transform some advises, such as to consider merger, develop healthy food, beef up the integrated supply chains, loosen the conditions of becoming a listed company or OTC(over-the-counter) company, value the intellectual property right and open overseas markets.
|
|---|
